Section 708A Cleansing Statement
Released
Released
Announcement PDF
ASX Announcement
5 May 2025
Section 708A Cleansing Statement
This Notice is given by Atomo Diagnostics Limited (ASX: AT1) (Atomo or the Company) under Section
708A(5)(e) of the Corporations Act 2001 (Cth) (Act):
The Company hereby confirms that:
a) it has today issued a total of 46,929,731 fully paid ordinary shares (Shares) to new and
existing professional, sophisticated and other exempt investors at an issue price of $0.0185
(1.85 cents) per Share as previously announced on 24 April 2025.
b) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
c) the Company is providing this notice under paragraph 5(e) of section 708A of the
Corporations Act;
d) as at the date of this notice, the Company has complied with:
i.
the provisions of Chapter 2M of the Act as they apply to the Company; and
ii.
section 674 and 674A of the Act; and
e) as at the date of this notice, there is no information that is “excluded information” (as defined
in sections 708A(7) and 708A(8) of the Act) which is required to be disclosed by the
Company.
The details of this allotment can be found within the Appendix 2A also announced on this day.
This announcement was authorised by the Managing Director & CEO on behalf of the Board.
~ ENDS ~
For more information, please contact:
John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279
Investor Queries
investorqueries@atomodiagnostics.com
About Atomo
Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid
diagnostic test (RDT) devices to the global diagnostic market.
Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability
across rapid point-of-care (POC) and at-home testing applications. The Company has successfully
commercialised a number of products across international markets and has supply agreements in place
for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial
differentiation and female health. See more at www.atomodiagnostics.com
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Share your feedback
Discover